<p>阿伯丁集團 plc 在最近向證券交易委員會的披露中表示，在第三季度將其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）中的持股增加了 21.3%。該公司在此期間購買了額外的 59,602 股後，持有該公司 339,949 股股票。截至最近向證券交易委員會的備案，阿伯丁集團 plc 擁有約 0.36% 的 Crinetics Pharmaceuticals，價值 14,159,000 美元。</p>
<p>其他一些機構投資者最近也買賣了該公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 11.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 59,311 股該公司的股票，價值 1,995,000 美元，此前在此期間購買了額外的 6,148 股。瑞銀資產管理美國有限公司的一個獨立業務部門在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 6.9%。瑞銀資產管理美國有限公司的這個獨立業務部門目前擁有 347,581 股該公司的股票，價值 11,658,000 美元，此前在此期間購買了額外的 22,305 股。Strs Ohio 在第一季度獲得了 Crinetics Pharmaceuticals 的新頭寸，價值約 124,000 美元。AlphaQuest LLC 在第二季度獲得了 Crinetics Pharmaceuticals 的新股份，價值 799,000 美元。最後，新澤西州共同養老金基金 D 在第二季度將其在 Crinetics Pharmaceuticals 的持股增加了 11.9%。新澤西州共同養老金基金 D 目前擁有 62,552 股該公司的股票，價值 1,799,000 美元，此前在上個季度購買了額外的 6,674 股。當前 98.51% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新目標價</h2>
<p>幾位研究分析師對 CRNX 股票發表了看法。高盛集團在 1 月 12 日的研究報告中將 Crinetics Pharmaceuticals 的評級從 “中性” 上調至 “買入”，並設定了 67.00 美元的目標價。華爾街 Zen 在 2 月 14 日的研究報告中將 Crinetics Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。Lifesci Capital 在 2 月 13 日的研究報告中將 Crinetics Pharmaceuticals 的評級上調至 “強力買入”。Citizens Jmp 在 1 月 8 日的報告中將 Crinetics Pharmaceuticals 的目標價從 108.00 美元下調至 105.00 美元，併為該公司設定了 “市場表現優於大盤” 的評級。最後，Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Crinetics Pharmaceuticals 的 “賣出（d-）” 評級。一位分析師對該股票給予了強力買入評級，九位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Crinetics Pharmaceuticals 當前的平均評級為 “適度買入”，共識目標價為 75.78 美元。</p>
<p><strong>查看我們關於 Crinetics Pharmaceuticals 的最新股票報告</strong></p>
<h2>Crinetics Pharmaceuticals 價格表現</h2>
<p>CRNX 週五開盤價為 44.00 美元。該公司的市值為 45 億美元，市盈率為 -9.71，貝塔值為 0.19。該公司的 50 日移動平均價格為 49.42 美元，200 日移動平均價格為 42.47 美元。Crinetics Pharmaceuticals, Inc. 的 52 周低點為 24.10 美元，52 周高點為 57.99 美元。</p>
<h2>Crinetics Pharmaceuticals 的內部活動</h2>
<p>在相關消息中，內部人士 Isabel Kalofonos 於 1 月 5 日星期一出售了 2,500 股該公司的股票。該股票以平均價格 55.00 美元出售，總交易額為 137,500.00 美元。交易完成後，內部人士在公司中持有 834 股，價值 45,870 美元。此交易代表其持股減少了 74.99%。該交易已在證券交易委員會的備案中披露，相關信息可通過 SEC 網站獲取。4.60% 的股票由公司內部人士持有。</p>
<h2>關於 Crinetics Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Crinetics Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化用於治療罕見內分泌疾病的新型治療藥物。該公司的專有平台利用對激素受體信號傳導的洞察，設計小分子候選藥物，以應對由激素活動失調引起的疾病。Crinetics 的研究工作集中在針對生長抑素、抗利尿激素和其他 GPCR 介導的通路，開發口服生物可用的分子，以提高患者的便利性和依從性。</p>
<p>該公司的主要產品候選藥物 paltusotine（前稱 CRN04777）是一種選擇性非肽類生長抑素受體 2 型激動劑，正在評估用於治療肢端肥大症和類癌綜合症腹瀉。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Crinetics Pharmaceuticals</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>我的愛潑斯坦故事</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
<p><strong>想看看其他對沖基金持有的 CRNX 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）的最新 13F 備案和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Crinetics Pharmaceuticals 並不在名單上。</p>
<p>儘管 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫療業 ETF - SPDR

基因改革 ETF - ARK

紐交所高增長板生物技術指數 ETF - First Trust

<p>阿伯丁集團 plc 在第三季度將其在 Crinetics Pharmaceuticals, Inc. 的股份增加了 21.3%，目前持有 339,949 股，價值 1416 萬美元。其他機構投資者也調整了他們的持股。分析師對 CRNX 的評級不一，高盛將其評級上調至 “買入”，並設定目標價為 67.00 美元。該股票開盤價為 44.00 美元，市值為 45 億美元。內部人士 Isabel Kalofonos 出售了 2,500 股，顯著減少了她的持股。Crinetics 專注於開發針對罕見內分泌疾病的治療藥物</p>

<p>Aberdeen Group plc boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 339,949 shares of the company's stock after buying an additional 59,602 shares during the period. Aberdeen Group plc owned approximately 0.36% of Crinetics Pharmaceuticals worth $14,159,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>阿伯丁集團 plc 在最近向證券交易委員會的披露中表示，在第三季度將其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）中的持股增加了 21.3%。該公司在此期間購買了額外的 59,602 股後，持有該公司 339,949 股股票。截至最近向證券交易委員會的備案，阿伯丁集團 plc 擁有約 0.36% 的 Crinetics Pharmaceuticals，價值 14,159,000 美元。</p>
</div><p>A number of other institutional investors have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals by 11.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company's stock valued at $1,995,000 after purchasing an additional 6,148 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Crinetics Pharmaceuticals by 6.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company's stock worth $11,658,000 after purchasing an additional 22,305 shares during the period. Strs Ohio acquired a new position in Crinetics Pharmaceuticals in the 1st quarter valued at approximately $124,000. AlphaQuest LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the 2nd quarter valued at $799,000. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Crinetics Pharmaceuticals by 11.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,552 shares of the company's stock valued at $1,799,000 after acquiring an additional 6,674 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也買賣了該公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 11.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 59,311 股該公司的股票，價值 1,995,000 美元，此前在此期間購買了額外的 6,148 股。瑞銀資產管理美國有限公司的一個獨立業務部門在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 6.9%。瑞銀資產管理美國有限公司的這個獨立業務部門目前擁有 347,581 股該公司的股票，價值 11,658,000 美元，此前在此期間購買了額外的 22,305 股。Strs Ohio 在第一季度獲得了 Crinetics Pharmaceuticals 的新頭寸，價值約 124,000 美元。AlphaQuest LLC 在第二季度獲得了 Crinetics Pharmaceuticals 的新股份，價值 799,000 美元。最後，新澤西州共同養老金基金 D 在第二季度將其在 Crinetics Pharmaceuticals 的持股增加了 11.9%。新澤西州共同養老金基金 D 目前擁有 62,552 股該公司的股票，價值 1,799,000 美元，此前在上個季度購買了額外的 6,674 股。當前 98.51% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several research analysts have weighed in on CRNX shares. The Goldman Sachs Group raised Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a research report on Monday, January 12th. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, February 14th. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Friday, February 13th. Citizens Jmp decreased their price objective on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a &#34;market outperform&#34; rating for the company in a report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $75.78.</p>
<div class="lb-trans"><p>幾位研究分析師對 CRNX 股票發表了看法。高盛集團在 1 月 12 日的研究報告中將 Crinetics Pharmaceuticals 的評級從 “中性” 上調至 “買入”，並設定了 67.00 美元的目標價。華爾街 Zen 在 2 月 14 日的研究報告中將 Crinetics Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。Lifesci Capital 在 2 月 13 日的研究報告中將 Crinetics Pharmaceuticals 的評級上調至 “強力買入”。Citizens Jmp 在 1 月 8 日的報告中將 Crinetics Pharmaceuticals 的目標價從 108.00 美元下調至 105.00 美元，併為該公司設定了 “市場表現優於大盤” 的評級。最後，Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Crinetics Pharmaceuticals 的 “賣出（d-）” 評級。一位分析師對該股票給予了強力買入評級，九位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Crinetics Pharmaceuticals 當前的平均評級為 “適度買入”，共識目標價為 75.78 美元。</p>
</div><p><strong>View Our Latest Stock Report on Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Crinetics Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Crinetics Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 價格表現</h2>
</div><p>CRNX opened at $44.00 on Friday. The company has a market capitalization of $4.50 billion, a P/E ratio of -9.71 and a beta of 0.19. The firm's fifty day moving average price is $49.42 and its two-hundred day moving average price is $42.47. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $24.10 and a fifty-two week high of $57.99.</p>
<div class="lb-trans"><p>CRNX 週五開盤價為 44.00 美元。該公司的市值為 45 億美元，市盈率為 -9.71，貝塔值為 0.19。該公司的 50 日移動平均價格為 49.42 美元，200 日移動平均價格為 42.47 美元。Crinetics Pharmaceuticals, Inc. 的 52 周低點為 24.10 美元，52 周高點為 57.99 美元。</p>
</div><h2>Insider Activity at Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的內部活動</h2>
</div><p>In related news, insider Isabel Kalofonos sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the transaction, the insider owned 834 shares in the company, valued at $45,870. This trade represents a 74.99% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Isabel Kalofonos 於 1 月 5 日星期一出售了 2,500 股該公司的股票。該股票以平均價格 55.00 美元出售，總交易額為 137,500.00 美元。交易完成後，內部人士在公司中持有 834 股，價值 45,870 美元。此交易代表其持股減少了 74.99%。該交易已在證券交易委員會的備案中披露，相關信息可通過 SEC 網站獲取。4.60% 的股票由公司內部人士持有。</p>
</div><h2>About Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Crinetics Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化用於治療罕見內分泌疾病的新型治療藥物。該公司的專有平台利用對激素受體信號傳導的洞察，設計小分子候選藥物，以應對由激素活動失調引起的疾病。Crinetics 的研究工作集中在針對生長抑素、抗利尿激素和其他 GPCR 介導的通路，開發口服生物可用的分子，以提高患者的便利性和依從性。</p>
</div><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p>
<div class="lb-trans"><p>該公司的主要產品候選藥物 paltusotine（前稱 CRN04777）是一種選擇性非肽類生長抑素受體 2 型激動劑，正在評估用於治療肢端肥大症和類癌綜合症腹瀉。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>My Epstein Story</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Crinetics Pharmaceuticals</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>我的愛潑斯坦故事</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CRNX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 CRNX 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免費報告）的最新 13F 備案和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Crinetics Pharmaceuticals 並不在名單上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX

Market Beat

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - Vanguard

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

Crinetics Pharmaceuticals

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

美國制藥 ETF - iShares

阿伯丁集團有限公司持有 Crinetics Pharmaceuticals, Inc. $CRNX 價值 1416 萬美元的股票